Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial

Immunotherapy

The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial

Allergy

Gappa M, Gagnon R, Horak F, Cichocka-Jarosz E, Dalgaard T, Hargreaves K, Mikler J, Emeryk A, Hansen KS, Pfaar O

doi: 10.1111/all.16363

Melanoma and Skin Cancer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Lancet Oncol

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

doi: 10.1016/S1470-2045(24)00338-3

Further Publications Dermatology

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials

J Eur Acad Dermatol Venereol

Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B

doi: 10.1111/jdv.20617

Further Publications Immunology

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Lancet

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie, Nordic Lymphoma Group, Australasian Leukaemia and Lymphoma Group

doi: 10.1016/S0140-6736(24)01315-1

Immunodeficiency

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

Clin Immunol

Rao VK, Šedivá A, Dalm VASH, Plebani A, Schuetz C, Shcherbina A, Trizzino A, Zharankova Y, Orpia A, Kulm E, Webster S, Körholz J, Lougaris V, Rodina Y, Conlon N, Coulter T, Bradt J, Relan A, Uzel G

doi: 10.1016/j.clim.2024.110400

Rosacea

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials

JAMA Dermatol

Bhatia N, Del Rosso J, Stein Gold L, Lain E, Draelos ZD, Sidgiddi S, MVOR-1 and MVOR-2 Study Investigators

doi: 10.1001/jamadermatol.2024.6542

Further Publications Immunology

A Streamlined Strategy for Basophil Activation Testing in a Multicenter Phase III Clinical Trial

J Allergy Clin Immunol Pract

Suárez-Fariñas M, Grishin A, Arif-Lusson R, Bourgoin P, Matthews K, Campbell DE, Busnel JM, Sampson HA

doi: 10.1016/j.jaip.2024.09.007

Atopic Dermatitis

Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

J Am Acad Dermatol

Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L

doi: 10.1016/j.jaad.2024.05.023

Osteoarthritis

Impact of Structural Severity on Outcomes in Knee Osteoarthritis: An Analysis of Data from Phase 2 and Phase 3 Lorecivivint Clinical Trials

Rheumatology (Oxford)

Tambiah J, Kennedy S, Swearingen C, McAlindon T, Yazici Y

doi: 10.1093/rheumatology/keae610

Related content